The use of statins and other lipid-lowering drugs is a valuable tool to prevent cardiovascular disease when dietary changes alone are insufficient.

“And if you remember what I just said, if you took everybody in their 20s and reduced them to a level of that of a child, you'd make ASCVD an orphan disease.”

Fibrates can effectively reduce major adverse cardiovascular endpoints in patients with insulin resistance.

“it reduced several microvascular endpoints in those trials to retinopathy amputations peripheral neuropathy renal disease even though you know fiber can raise creatinine a little bit GFR improved and renal outcomes improved”

Metformin is a valuable drug for reducing hepatic glucose output but it is not a true insulin sensitizer and does not enter muscle cells.

“Metformin is not a true insulin sensitizer that total misconception”

High-dose EPA (4 grams daily) is a valuable adjunct to statin therapy for reducing residual cardiovascular risk.

“lo and behold and we haven't come up with much in the world so far at least it has a big trial saying we lower residual risk with a statin isetami did it in acute carne syndrome survivors to a certain degree but this high-dose epa two grams twice a day with food because it is an ethyl ester theoreti”

Using performance-enhancing hormones without proper medical knowledge and management of side effects can be detrimental to one's appearance.

“I would never say something as ridiculous as that because I understand that people aren't going to really understand all the nuance and a lot of the times stuff like that can actually make you worse looking if you don't understand things like, you know, how to manage your side effects.”

The speaker identifies several significant risks associated with weight loss drugs, including muscle mass loss, pancreatitis, and potential unknown long-term brain effects.

“one of the ones that was most disconcerting and was explained to me by a brilliant scientist called Greg Stanwood who Florida State University and is researching these drugs the biggest risk is what he called unknown unknown”

Treating Parkinson's disease with L-dopa can inadvertently trigger compulsive behaviors in some patients because the medication increases dopamine levels non-specifically throughout the brain.

“it binds non-specifically throughout the brain so that means that that that dopamine I gave you is now binding to dopamine receptors in the reward pathway and we see is about a quarter of people treated with l-dopa for Parkinson's end up with some kind of compulsive consumptive Behavior”